Ward K N, Dhaliwal W, Ashworth K L, Clutterbuck E J, Teo C G
Department of Virology, Royal Postgraduate Medical School, University of London, United Kingdom.
J Med Virol. 1994 Aug;43(4):367-72. doi: 10.1002/jmv.1890430409.
A new IgG antibody avidity test for hepatitis C virus (HCV) has been developed and was validated using sera from 12 renal dialysis patients infected with HCV. In primary HCV infection low avidity antibody (mean avidity index 24%) was detected within 50 days of seroconversion whereas in long-term infection (at least 300 days after seroconversion), the mean avidity index was high (88%); in five patients, the avidity index was shown to increase rapidly as time elapsed after primary infection, whereas immunosuppressive therapy was found to delay maturation of the immune response in two further patients. The assay was then employed to confirm that a spurious outbreak of primary HCV infection in eight bone marrow transplant patients was explicable by passive acquisition of high avidity anti-HCV after intravenous immunoglobulin therapy. It is concluded that this avidity test will have an important role in the investigation of HCV infection in patients.
已研发出一种针对丙型肝炎病毒（HCV）的新型IgG抗体亲和力检测方法，并使用12名感染HCV的肾透析患者的血清进行了验证。在原发性HCV感染中，血清转换后50天内检测到低亲和力抗体（平均亲和力指数为24%），而在长期感染中（血清转换后至少300天），平均亲和力指数较高（88%）；在5名患者中，亲和力指数显示在原发性感染后随时间迅速增加，而在另外2名患者中发现免疫抑制疗法会延迟免疫反应的成熟。然后采用该检测方法来确认，8名骨髓移植患者中假性原发性HCV感染暴发可通过静脉注射免疫球蛋白治疗后被动获得高亲和力抗HCV来解释。得出的结论是，这种亲和力检测方法将在患者HCV感染调查中发挥重要作用。
